Accumulated Clinical Experiences from Successful Treatment of 1377 Severe and Critically Ill COVID-19 Cases

被引：0

作者：

Yong Gao

Hai-bo Qiu

Shu Zhou

Zhen-ning Wang

Jian-chu Zhang

Zheng-liang Zhang

Zhao-xin Qian

Hong-bo Wang

Shi-huan Yu

Yi-feng Luo

Ya-dan Wang

Zhuang Liu

Wei-ci Wang

Ming Jia

Li-ming Zhang

Yu Zhang

Yang Jin

Yong Zhang

Yong Liu

Zi-hua Zhou

Ying Su

Hui-qing Li

Wei-min Xiao

Kai Huang

Ping He

Gang Li

Zhao-hui Fu

Shi Liu

Neng-xing Lin

Fan-jun Cheng

机构：

[1] Huazhong University of Science and Technology,Union Hospital, Tongji Medical College

[2] Zhongda Hospital of Southeast University,undefined

[3] The First Affiliated Hospital of China Medical University,undefined

[4] The Second Affiliated Hospital of Xi’an Jiaotong University,undefined

[5] Xiangya Hospital of Zhongnan University,undefined

[6] The First Affiliated Hospital of Harbin Medical University,undefined

[7] The First Affiliated Hospital of Sun Yat-sen University,undefined

[8] Beijing Friendship Hospital of Capital Medical University,undefined

[9] Beijing Anzhen Hospital of Capital Medical University,undefined

[10] Beijing Chaoyang Hospital of Capital Medical University,undefined

来源：

Current Medical Science | 2020年 / 40卷

关键词：

2019-nCoV; COVID-19; pneumonia; treatment; guidelines;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In late December 2019, COVID-19 was firstly recognized in Wuhan, China and spread rapidly to all of the provinces of China. The West Campus of Wuhan Union Hospital, the designated hospital to admit and treat the severe and critically ill COVID-19 cases, has treated a large number of such patients with great success and obtained lots of valuable experiences based on the Chinese guideline (V7.0). To standardize and share the treatment procedures of severe and critically ill cases, Wuhan Union Hospital has established a working group and formulated an operational recommendation, including the monitoring, early warning indicators, and several treatment principles for severe and critically ill cases. The treatment experiences may provide some constructive suggestions for treating the severe and critically ill COVID-19 cases all over the world.

引用

页码：597 / 601

页数：4

共 36 条

[1] Wang DW(2020)Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China JAMA 323 1061-1069
[2] Hu B(2020)A pneumonia outbreak associated with a new coronavirus of probable bat origin Nature 579 270-273
[3] Hu C(2020)Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China Lancet 395 497-506
[4] Zhou P(2020)A pathological report of three COVID-19 cases by minimally invasive autopsies Zhonghua Bing Li Xue Za Zhi (Chinese) 49 E009-473
[5] Yang X(2020)A novel coronavirus outbreak of global health concern Lancet 395 470-513
[6] Wang X(2020)Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study Lancet 395 507-1799
[7] Huang C(2020)A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19 N Engl J Med 382 1787-e5
[8] Wang Y(2020)Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study J Infect 81 e1-e23
[9] Li X(2020)Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19 J Infect 81 e21-2336
[10] Yao XH(2020)Compassionate Use of Remdesivir for Patients with Severe Covid-19 N Engl J Med 382 2327-1263

← 1 2 3 4 →